Edition:
United States

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.11USD
22 Jun 2018
Change (% chg)

$0.11 (+1.83%)
Prev Close
$6.00
Open
$6.00
Day's High
$6.12
Day's Low
$6.00
Volume
7,559
Avg. Vol
4,098
52-wk High
$7.95
52-wk Low
$5.80

Chart for

About

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcyste... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $95.99
Shares Outstanding(Mil.): 15.71
Dividend: --
Yield (%): --

Financials

  CPIX.OQ Industry Sector
P/E (TTM): -- 29.56 34.14
EPS (TTM): -0.58 -- --
ROI: -12.22 13.56 13.10
ROE: -13.91 15.35 15.09

BRIEF-Cumberland Pharmaceuticals Reports Q1 Adjusted Loss Per Share $0.09

* CUMBERLAND PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Cumberland Pharmaceuticals Expands Into Oncology Support

* CUMBERLAND PHARMACEUTICALS EXPANDS INTO ONCOLOGY SUPPORT Source text for Eikon: Further company coverage:

Apr 09 2018

BRIEF-Cumberland Pharmaceuticals- Entered Agreement With Gastro-Entero Logic To Acquire Assets Associated With Omeclamox((Reg))-Pak

* CUMBERLAND PHARMACEUTICALS-ON MARCH 13, ENTERED AGREEMENT WITH GASTRO-ENTERO LOGIC, LLC TO ACQUIRE ASSETS ASSOCIATED WITH OMECLAMOX -PAK

Mar 16 2018

BRIEF-Cumberland Pharma Q4 Adjusted Earnings Per Share $0.03

* CUMBERLAND PHARMACEUTICALS REPORTS 25% REVENUE GROWTH FOR THE FULL YEAR 2017

Mar 06 2018

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage:

Jan 30 2018

Earnings vs. Estimates